# Feasibility Study of the FARAFLEX Mapping and PFA System

Study · id `cardio:ct-nct06510556` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06510556](<https://clinicaltrials.gov/study/NCT06510556>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06510556

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 250 participants.

## Technical summary

Registry record NCT06510556. Non-randomized; no masking; primary purpose treatment. Start 2025-02-17 (actual); primary completion 2027-02-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 250 participants (planned count; ClinicalTrials.gov record NCT06510556, source copy `cardio:ctgov-nct06510556-2026-10-23`, retrieved 2026-10-26)
- Started: 2025-02-17 (actual) (ClinicalTrials.gov record NCT06510556, source copy `cardio:ctgov-nct06510556-2026-10-23`, retrieved 2026-10-26)
- Primary completion: 2027-02-15 (anticipated) (ClinicalTrials.gov record NCT06510556, source copy `cardio:ctgov-nct06510556-2026-10-23`, retrieved 2026-10-26)
- Completion: 2027-09-15 (anticipated) (ClinicalTrials.gov record NCT06510556, source copy `cardio:ctgov-nct06510556-2026-10-23`, retrieved 2026-10-26)
- Countries: Belgium; Croatia; Czechia; Italy (ClinicalTrials.gov record NCT06510556, source copy `cardio:ctgov-nct06510556-2026-10-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06510556-2026-10-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Feasibility Study of the FARAFLEX Mapping and PFA System
- Acronym: ELEVATE-PF
- Condition: Atrial Fibrillation
- Condition: Persistent Atrial Fibrillation
- Condition: Paroxysmal AF
- Intervention (Device): FARAFLEX Ablation Treatment
- Intervention (Device): ELEVATE-COR Sub-study
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: e3a859610ff457121bbb4544d0fb4b485e86cf65eb20d086334cd89094754c44
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
